Navigation Links
Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkin's Lymphoma
Date:12/10/2007

SEATTLE, Dec. 10 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced that Wyeth Pharmaceuticals has initiated a Phase I/II clinical trial of TRU-015, Trubion's lead Small Modular ImmunoPharmaceutical (SMIP(TM)) drug candidate, for the treatment of non-Hodgkin's lymphoma (NHL). The nonrandomized, open label, uncontrolled, single-group assignment clinical trial is designed to evaluate the safety and efficacy of TRU-015 in subjects with NHL. Trubion is co-developing TRU-015 and other CD20-directed therapies with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE).

"We believe that TRU-015 may be a valuable tool in the treatment of NHL, and we are looking forward to working with Wyeth as this development program moves forward," said Peter Thompson, M.D., FACP, president, chief executive officer and chairman of Trubion.

TRU-015 Phase I/II Clinical Trial Protocol

The Phase I/II clinical trial is expected to enroll approximately 120 NHL subjects who have undergone two or more prior therapies and have relapsed or refractory disease. Efficacy will be evaluated according to disease response and progression status per the International Response Criteria for NHL. Participants will receive an escalating dose of four weekly infusions of TRU-015. Once a maximum tolerated dose is confirmed, or once a maximum dose to be studied is determined to be safe and well tolerated, an expanded cohort of subjects with relapsed follicular NHL will be evaluated for efficacy.

Trubion
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 ... of the "Physician Office Laboratory Markets, 3rd ... This report, Physician Office Laboratory Markets is ... the IVD industry. Physician office laboratories are diverse ... simply perform reimbursable, in-office pregnancy and glucose tests. ...
(Date:9/23/2014)... The Pennsylvania State Police will accept unwanted, expired ... of National Prescription Drug Take-Back Day. The service is ... Day is a national initiative, conducted in partnership with ... the public to dispose of expired, unused or unwanted ... From 10 a.m. to 2 p.m., unwanted ...
(Date:9/23/2014)... , Sept. 23, 2014 Research and ... "Biopharmaceutical and Vaccine Production Markets" report to their ... new therapies and vaccines - including products to treat ... still huge challenges during the final stages of clinical ... and how to risk production capital to upscale while ...
Breaking Medicine Technology:Physician Office Laboratory Markets, 3rd Edition 2Physician Office Laboratory Markets, 3rd Edition 3Biopharmaceutical and Vaccine Production Markets 2Biopharmaceutical and Vaccine Production Markets 3
... Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), ... and commercialization of its proprietary stent platform technology, ... summary of  three years collective data will be ... Transcatheter Cardiovascular Therapeutics (TCT) conference. The conference is ...
... Express Scripts, Inc., one of the largest ... Rexam as its 2011 Supplier of the Year. ... This award recognizes suppliers who have a ... continuous improvement in supplier relationship management, quality, service, ...
Cached Medicine Technology:InspireMD to Sponsor Satellite Symposium Breakfast Meeting Chaired by Dr. Gregg W. Stone November 9th at TCT 2011 2InspireMD to Sponsor Satellite Symposium Breakfast Meeting Chaired by Dr. Gregg W. Stone November 9th at TCT 2011 3InspireMD to Sponsor Satellite Symposium Breakfast Meeting Chaired by Dr. Gregg W. Stone November 9th at TCT 2011 4Rexam Chosen as Express Scripts' Supplier of the Year 2
(Date:9/23/2014)... 2014 The inaugural single day event ... Hotel New Otani Tokyo Gardens in Tokyo. Clinical data scientists ... and validation. , The second single day event in ... offices in Shanghai. The clinical data scientists attending this event ... figures and listings, which display data collected in clinical studies ...
(Date:9/23/2014)... "The primary purpose of the CALL LIGHT ... from Sacramento, Ca.. "Call lights are often found on the ... the IV pole out of the patient's reach. In order ... whenever they need it, I created this caddy." , She ... call device within easy reach. The accessory ensures that the ...
(Date:9/23/2014)... Downingtown, PA (PRWEB) September 24, 2014 ... traumatic stress disorder (PTSD) – and how it can ... 31, was deployed in Iraq in 2006. His platoon ... home in 2008, he was diagnosed with combat-related PTSD ... withdrawn, I was angry, and I had distanced myself ...
(Date:9/23/2014)... Karen Pallarito HealthDay Reporter ... if doctors and hospitals got paid for providing better ... better data for making informed health choices. A ... is headed. The report, from the IMS Institute for ... -- recent events expected to alter the delivery of health ...
(Date:9/23/2014)... 2014 What information do patients ... Quality Forum (NQF) released a report ( http://bit.ly/1DwekE9 ... an infographic ( http://bit.ly/1tX3lzA ) resulting from an ... how patients define affordability, and what information and ... best possible healthcare at the lowest possible cost. ...
Breaking Medicine News(10 mins):Health News:PhUSE Further Expands its Global Community Into the Asian Region 2Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Report Identifies Game Changers for U.S. Health Care 2Health News:Report Identifies Game Changers for U.S. Health Care 3Health News:Finding Affordable Care: Asking the Right Question is Key 2
... , , , ROCHESTER, Minn., Sept. ... is the focus of a Perspectives article in ... 23, 2009, and in the print issue on Oct. 1, 2009. , ... , "We must hold physicians and other providers accountable for ...
... from the dried venom secreted by the skin glands of ... those normally administered, and may slow disease progression in some ... D. Anderson Cancer Center. The results from ... M. D. Anderson and Fudan University Cancer Hospital in Shanghai, ...
... The Weill Cornell Institute of Geriatric Psychiatry at ... the largest grant in its 20-year history. One ... million, five-year "Center Grant" from the National Institute ... investigators to advance their pioneering work in understanding ...
... registered in the past 30 years, cardiovascular disease (CVD) remains the ... In the EU, experts reveal that striking disparities still exist ... with regard to national prevention policies. In view of this, there ... tackle heart disease and stroke. The message coincides with ...
... ... ... -- Whether in a quest for beauty or out of necessity, millions of Americans will ... technologies, and research will be presented at Plastic Surgery 2009, the annual scientific meeting of ...
... flu not effective , THURSDAY, Sept. 24 (HealthDay News) ... give the wrong dose of Tamiflu to their children ... dosing instructions don,t always coincide with the measurement markings ... , The warning letter, penned by scientists from Northwestern ...
Cached Medicine News:Health News:Mayo Clinic Offers Perspective on Health Care Reform in New England Journal of Medicine 2Health News:M. D. Anderson examines use of toad venom in cancer treatment 2Health News:M. D. Anderson examines use of toad venom in cancer treatment 3Health News:Weill Cornell Institute for Geriatric Psychiatry awarded $10 million grant 2Health News:Weill Cornell Institute for Geriatric Psychiatry awarded $10 million grant 3Health News:Weill Cornell Institute for Geriatric Psychiatry awarded $10 million grant 4Health News:World Heart Day resonates with recent experts' findings on CVD and EU institutions' determination to promote heart health 2Health News:World Heart Day resonates with recent experts' findings on CVD and EU institutions' determination to promote heart health 3Health News:American Society Of Plastic Surgeons Hosts 78th Annual Meeting 2Health News:American Society Of Plastic Surgeons Hosts 78th Annual Meeting 3Health News:American Society Of Plastic Surgeons Hosts 78th Annual Meeting 4Health News:Letter Warns About Tricky Dosing With Liquid Tamiflu for Kids 2Health News:Letter Warns About Tricky Dosing With Liquid Tamiflu for Kids 3
... Bio-Rad isotopic anemia ... and minimal ,pipetting steps ... information about the processes ... and the benefit to ...
... Bio-Rad isotopic anemia assays ... minimal ,pipetting steps for ... about the processes ,involved ... the benefit to your ...
... The ImmunoDOT Autoimmunity Screening Panel ... test for screening and detection,of autoantibodies ... DNA, SS-A/SS-B, RNP/Sm) in serum, and ... diagnosis of systemic lupus erythematosus (SLE), ...
The MESACUP ANA Test Kit is a semi-quantitative enzyme-linked immunosorbent assay,(ELISA) for the detection of specific anti-nuclear antibodies in human serum as an aid in,the determination of autoim...
Medicine Products: